hpv vaccination: the beginning of the end of cervical cancer? - a review
Clicks: 288
ID: 129560
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
288 views
39 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #61 of 450 articles by views in kurdistan journal of applied research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 450 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Human papillomavirus (HPV) is responsible for all cases of cervical cancer, as well as a great percentage of other anogenital tumors and oropharyngeal tumors. Since the main etiologic factor for these diseases is a virus, prophylactic measures are the best way to reduce the burden caused by the infection and associated disease. This review brings up to date information on the two commercially available prophylactic HPV vaccines against HPV, as well as presenting the ongoing research on HPV peptide, protein and dendritic cell based therapeutic vaccines.
| Reference Key |
lepique2009memriashpv
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ana Paula Lepique;Tatiana Rabachini;Luisa Lina Villa |
| Journal | kurdistan journal of applied research |
| Year | 2009 |
| DOI |
10.1590/S0074-02762009000100001
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.